BCAX

MKT CAP:$1B

Bicara Therapeutics Inc. Common Stock

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$22.72+$6.34 (+38.68%)

Apr 24, 2026

Company Details

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) di...

CEO

Claire Mazumdar Clemon

IPO Date

Sep 13, 2024

Website

www.bicara.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$138M

EPS (Diluted)

-$2.53

Free Cash Flow

-$107M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$2.52

Q4 2025

Mar 30, 2026

$0EPS -$0.68

Q3 2025

Nov 10, 2025

$0EPS -$0.67

Q2 2025

Aug 12, 2025

$0EPS -$0.50

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 23	$0	$0	-$8M
Q2 23	$0	$0	-$8M
Q3 23	$0	$0	-$10M
Q4 23	$0	$0	-$14M
Q1 24	$0	$0	-$15M
Q2 24	$0	$0	-$20M
Q3 24	$0	$0	-$21M
Q4 24	$0	$0	-$27M
Q1 25	$0	$0	-$42M
Q2 25	$0	$0	-$32M
Q3 25	$0	$0	-$41M
Q4 25	$0	$0	-$41M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$14M	-$14M
Q2 23	-$14M	-$14M
Q3 23	-$11M	-$11M
Q4 23	-$8M	-$8M
Q1 24	-$15M	-$15M
Q2 24	-$13M	-$13M
Q3 24	-$17M	-$17M
Q4 24	-$30M	-$30M
Q1 25	-$28M	-$28M
Q2 25	-$26M	-$26M
Q3 25	-$29M	-$29M
Q4 25	-$24M	-$24M

Capital Expenditures

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$150.0K
Q4 23	$436.0K
Q1 24	$4.0K
Q2 24	$19.0K
Q3 24	$8.0K
Q4 24	$40.0K
Q1 25	$0
Q2 25	$0
Q3 25	$42.0K
Q4 25	$238.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 24	—	+84.4%
Q2 24	—	+136.9%
Q3 24	—	+116.5%
Q4 24	—	+94.6%
Q1 25	—	+171.8%
Q2 25	—	+62.1%
Q3 25	—	+97.2%
Q4 25	—	+54.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$307.5K	—
Q2 23	$307.5K	—
Q3 23	$519.0K	—
Q4 23	$765.0K	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$2M	—
Q4 24	$3M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$4M	—
Q4 25	$4M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$7M	$2M
Q2 23	$7M	$2M
Q3 23	$7M	$3M
Q4 23	$11M	$3M
Q1 24	$12M	$3M
Q2 24	$16M	$4M
Q3 24	$16M	$5M
Q4 24	$20M	$7M
Q1 25	$34M	$7M
Q2 25	$25M	$7M
Q3 25	$6M	$8M
Q4 25	$33M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$0	$0	$0
Q4 23	$230M	$0	$230M
Q1 24	$204M	$0	$204M
Q2 24	$204M	$0	$204M
Q3 24	$521M	$0	$521M
Q4 24	$490M	$0	$490M
Q1 25	$462M	$0	$462M
Q2 25	$437M	$0	$437M
Q3 25	$172M	$118M	$290M
Q4 25	$97M	$318M	$415M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 23	55M	—	—
Q2 23	55M	0.0%	—
Q3 23	54M	-0.4%	—
Q4 23	53M	-2.4%	—
Q1 24	54M	+2.1%	-0.8%
Q2 24	54M	0.0%	-0.8%
Q3 24	54M	+0.4%	0.0%
Q4 24	54M	+0.1%	+2.6%
Q1 25	54M	+0.0%	+0.5%
Q2 25	55M	+0.2%	+0.7%
Q3 25	55M	+0.0%	+0.3%
Q4 25	55M	+1.1%	+1.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	200K
Q1 25	$0	200K
Q2 25	$0	200K
Q3 25	$0	200K
Q4 25	$0	200K

Revenue / Employee